Private Equity Investor PLCPress Releases
About the Fund
Our Portfolio
Company Personnel
Annual Report
Interim Report
Regulatory News
General Meetings
Press Releases
Articles of Association
Share Price
Home
4th Floor, 23 Bentinck Street, London W1U 2EZ - Tel +44 (0)20 7563 1630 - Fax +44 (0)20 7486 4534
Net Asset Value 228.06p/341.20¢ inc. current period deficit; 228.73p/342.20¢ exc. current period deficit
per ordinary share at 30 June 2010 incorporating unaudited Revenue Reserves to 31 May 2010 (exchange rate, £1=US$1.4961).
For Limited Partnerships Revaluations see Our Portfolio.
Registered office
Beaufort House
51 New North Road
Exeter, EX4 4EP
Company Number
3912487 – England & Wales


HACKER SAFE certified sites prevent over 99.9% of hacker crime.
Connector
Opening the doors to world class opportunity at the venture stage
Linking IT investment in the UK and USA

14 DECEMBER 2007

TR-1 (i) Notification of Major Interests in Shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

Private Equity Investor Plc

2. Reason for the notification State Yes/No
An acquisition or disposal of voting rights  
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached  
An event changing the breakdown of voting rights  
Other (please specify): Shares tendered by company Yes

3. Full name of person(s) subject to the notification obligation (iii): Deutsche Bank AG
4. Full name of shareholder(s) (if different from 3.) (iv):  
5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v): N/A
6. Date on which issuer notified: 13/12/07
7. Threshold(s) that is/are crossed or reached: Direct 17%’3% Aggregate Direct & Indirect 21%’%
8. Notified details:  

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE Situation previous to the Triggering transaction (vi) Resulting situation after the triggering transaction (vii)
  Number of Shares Number of Voting Rights (viii) Number of shares Number of voting rights (ix) % of voting rights
      Direct Direct (x) Indirect (xi) Direct Indirect
GB0000504034 8,844,268 10,595,523 Below 3% Below 3%     Below 3%

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument Expiration date (xiii) Exercise/Conversion Period/ Date (xiv) Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights
         

Total (A+B)  
Number of voting rights % of voting rights
Below 3% Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

 

Proxy Voting:

10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A
12. Date on which proxy holder will cease to hold voting rights: N/A

13. Additional information: N/A


Notes to editors
The Company seeks to achieve substantial capital appreciation by investing in emerging growth companies through specialised US venture capital funds focused on the information technology, biotechnology and healthcare sectors.


Return to Press Release Index